Overcoming resistance to BRAFV600E inhibition in melanoma by deciphering and targeting personalized protein network alterations
Abstract BRAFV600E melanoma patients, despite initially responding to the clinically prescribed anti-BRAFV600E therapy, often relapse, and their tumors develop drug resistance. While it is widely accepted that these tumors are originally driven by the BRAFV600E mutation, they often eventually diverg...
Guardado en:
Autores principales: | S. Vasudevan, E. Flashner-Abramson, Heba Alkhatib, Sangita Roy Chowdhury, I. A. Adejumobi, D. Vilenski, S. Stefansky, A. M. Rubinstein, N. Kravchenko-Balasha |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/3fa3ce4bd8c843c780d29b16c0e89e36 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
IMMUNOHISTOCHEMICAL EXPRESSION OF BRAFV600E IN MELANOMA CASES
por: Muhammad Umer Ch, et al.
Publicado: (2021) -
BRAFV600E negatively regulates the AKT pathway in melanoma cell lines.
por: Brenden Chen, et al.
Publicado: (2012) -
SIRT6 haploinsufficiency induces BRAFV600E melanoma cell resistance to MAPK inhibitors via IGF signalling
por: Thomas Strub, et al.
Publicado: (2018) -
Synergistic activation of mutant TERT promoter by Sp1 and GABPA in BRAFV600E-driven human cancers
por: Yongxing Wu, et al.
Publicado: (2021) -
BRAFV600E induces reversible mitotic arrest in human melanocytes via microrna-mediated suppression of AURKB
por: Andrew S McNeal, et al.
Publicado: (2021)